Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.

van Koningsbruggen-Rietschel, S; Heuer, H E; Merkel, N; Posselt, H G; Staab, D; Sieder, C; Ziegler, J; Krippner, F; Rietschel, E

van Koningsbruggen-Rietschel, S; Heuer, H E; Merkel, N; Posselt, H G; Staab, D; Sieder, C; Ziegler, J; Krippner, F; Rietschel, E.

Affiliation

van Koningsbruggen-Rietschel S; CF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany silke.vankoningsbruggen@uk-koeln.de.
Heuer HE; CF Center, Hamburg-Altona, Germany.
Merkel N; University Children's Hospital, Halle, Germany.
Posselt HG; University Children's Hospital, Frankfurt, Germany.
Staab D; CF Center, Children's Hospital Charité, Berlin, Germany.
Sieder C; Novartis Pharma GmbH, Nuernberg, Germany.
Ziegler J; Novartis Pharma GmbH, Nuernberg, Germany.
Krippner F; Novartis Pharma GmbH, Nuernberg, Germany.
Rietschel E; CF Center, Children's Hospital, Faculty of Medicine, University of Cologne, Cologne, Germany.

J Antimicrob Chemother ; 71(3): 711-7, 2016 Mar.

Article in En | MEDLINE | ID: mdl-26626719

Subject(s)

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pseudomonas Infections / Tobramycin / Pneumonia, Bacterial / Cystic Fibrosis / Anti-Bacterial Agents Type of study: Clinical_trials / Prognostic_studies Limits: Adolescent / Adult / Child / Female / Humans / Male Language: En Journal: J Antimicrob Chemother Year: 2016 Document type: Article Affiliation country: Alemania Country of publication: Reino Unido

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google